Partnering Strategy

The SciFluor pipeline contains novel and differentiated small molecule compounds in a wide range of disease and therapeutic categories including neurology, ophthalmology, fibrosis and inflammation. Patents have been filed on promising candidates that have advanced into various stages of development. The company’s business strategy focuses on establishing collaborative partnerships to drive fluorine-enabled new chemical entities through development and commercialization to address unmet commercial and clinical needs.



SciFluor News

SciFluor Life Sciences Announces First Patients Dosed in Retinal Program with Investigational New Drug Application for SF0166 Topical Ophthalmic Solution
read more >

SciFluor Life Sciences Enters Clinical Trial Stage for Novel Treatment for Retinal Diseases
read more >

SciFluor Life Sciences Awarded Second U.S. Patent for Integrin αvβ3 (SF0166) Inhibitors Designed for the Topical Treatment of Retinal Disease
read more >

SciFluor Life Sciences Patented Compound SF0034 Highlighted in Research Published in The Journal of Neuroscience
read more >

SciFluor Life Sciences Raises $30 Million and Names William Koster, PhD, Former CEO of Neurogen Corp., as Chairman
read more >

SciFluor Life Sciences Awarded U.S. Patent for KCNQ2/3 Activator Designed for Treatment of Epilepsy and Related Neurological Disorders
read more >